千红制药(002550) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 was ¥450,880,337.41, a decrease of 2.22% compared to ¥461,101,487.65 in the same period last year[6] - Net profit attributable to shareholders increased by 54.62% to ¥160,968,397.92 from ¥104,108,160.35 year-on-year[6] - Basic and diluted earnings per share rose by 55.74% to ¥0.1288 from ¥0.0827 in the same period last year[6] - Total operating revenue for the current period is $450.88 million, a decrease of 2.6% from $461.10 million in the previous period[19] - Net profit for the current period is $157.61 million, an increase of 55.6% compared to $101.35 million in the previous period[20] Cash Flow - The net cash flow from operating activities decreased by 58.21% to ¥71,511,688.25, down from ¥171,109,914.54 in the previous year[6] - Cash flow from operating activities generated a net amount of $71.51 million, a decrease of 58.3% from $171.11 million in the previous period[22] - The company reported a net increase of ¥46,901,300 in cash flow from investing activities, attributed to maturing bank financial products[10] - Cash flow from investing activities generated a net amount of $127.99 million, an increase from $81.09 million in the previous period[22] Assets and Liabilities - Total assets increased by 4.16% to ¥2,948,304,157.01 compared to ¥2,830,441,261.34 at the end of the previous year[6] - The company's cash and cash equivalents increased to ¥638,549,089.41 from ¥439,945,400.01, representing a growth of approximately 45.2%[16] - The company's total liabilities decreased to ¥274,026,522.27 from ¥313,870,622.96, reflecting a reduction of approximately 12.7%[17] - Total assets rose to ¥2,948,304,157.01, up from ¥2,830,441,261.34, indicating an increase of about 4.2%[17] - The total equity attributable to the parent company increased to ¥2,678,508,814.41 from ¥2,517,442,607.50, marking a growth of around 6.4%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 57,296, with the largest shareholder holding 19.96% of the shares[12] Inventory and Receivables - Accounts receivable rose to ¥311,016,437.94 from ¥254,387,636.49, which is an increase of approximately 22.2%[16] - Inventory decreased to ¥367,041,802.35 from ¥426,812,563.07, showing a decline of about 13.9%[16] Other Financial Metrics - The weighted average return on equity improved to 6.20%, up from 4.31% year-on-year, reflecting better profitability[6] - The company recovered overdue payments from the Jian Yuan Trust, contributing to the significant increase in net profit[9] - The decrease in revenue was primarily due to a decline in the export price of raw materials compared to the previous year[9] - The company experienced a significant increase in credit impairment losses, totaling $52.62 million, compared to a reversal of $6.06 million in the previous period[19] - The company reported a tax expense of $29.43 million, compared to $15.49 million in the previous period, reflecting an increase of 90.1%[20] - Other comprehensive income after tax for the current period is $97,808.99, compared to a loss of $1.32 million in the previous period[20]